Compare RGTI & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGTI | GPCR |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.8B |
| IPO Year | 2021 | 2023 |
| Metric | RGTI | GPCR |
|---|---|---|
| Price | $15.48 | $47.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $30.78 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 17.8M | 540.7K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,102,000.00 | N/A |
| Revenue This Year | $225.06 | N/A |
| Revenue Next Year | $99.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 59.86 | N/A |
| 52 Week Low | $12.53 | $18.49 |
| 52 Week High | $58.15 | $94.90 |
| Indicator | RGTI | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 39.65 |
| Support Level | $15.30 | $46.40 |
| Resistance Level | $16.30 | $56.63 |
| Average True Range (ATR) | 1.01 | 2.23 |
| MACD | -0.19 | -0.66 |
| Stochastic Oscillator | 0.94 | 0.99 |
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.